Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering ...

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, ...

Equities researchers at Leerink Partnrs issued their Q1 2025 EPS estimates for argenx in a research report issued to clients ...

Stock analysts at Leerink Partnrs issued their FY2029 earnings per share (EPS) estimates for Schrödinger in a research report issued to clients and investors on Wednesday, February 26th. Leerink ...

Leerink analyst Faisal Khurshid downgraded Pliant Therapeutics (PLRX) to Market Perform from Outperform with a price target of $2, down from ...

Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat ...

Leerink downgraded Pliant Therapeutics (PLRX) to Market Perform from Outperform with a $2 price target Discover the Best Stocks and Maximize ...

Tenax Therapeutics, Inc. is a Phase 3, development-stage pharmaceutical company focused on developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet ...

Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases ...

For those investors interested in scheduling a one-on-one meeting with the Remix management team, please contact your Leerink representative.

Molecular Partners will present at TD Cowen and Leerink healthcare conferences and host a financial results call on March 7. Molecular Partners AG, a clinical-stage biotech company focused on ...

Tuesday, Leerink Partners began coverage on Maze Therapeutics shares (NASDAQ:MAZE), currently trading at $10.82 with a market capitalization of $525 million, assigning an Outperform rating and a price ...